Date: 2016-01-05
Type of information: Licensing agreement
Compound: biosimilar version of darbepoetin Alfa
Company: Fuji Pharma (Japan) Chong Kun Dang Pharmaceutical (Republic of Korea)
Therapeutic area: Kidney diseases - Renal diseases
Type agreement: licensing
Action mechanism: protein/biosimilar. Darbepoetin Alfa is an erythropoiesis-stimulating agent (ESA) with long acting effects. The
drug is effective for improving renal anemia seen in patients with non-dialysis chronic kidney disease and in hemodialysis patients.
Disease: renal anemia
Details: * On January 5, 2016, Fuji Pharma announced that the company has signed a license agreement with Chong Kun Dang Pharmaceutical Corp. Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of darbepoetin alfa biosimilar.
Darbepoetin Alfa Biosimilar, launched in 2013, is Fuji Pharma’s second biosimilar product following Filgrastim BS injection Syringe (F), a recombinant human granulocyte colony-stimulating factor (G-CSF) drug.
Financial terms:
Latest news:
